A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors
In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2018-11-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/a-paradigm-shift-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hr-her2-advanced-breast-cancer-a-review-of-cdk-inhibitors |
id |
doaj-5e1b8b58681343a2a90c0ae761a28613 |
---|---|
record_format |
Article |
spelling |
doaj-5e1b8b58681343a2a90c0ae761a286132020-11-25T00:31:03ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982018-11-0171610.7573/dic.212555A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitorsMariane Teodoro FernandesJacob J AdashekCarmelia Maria Noia BarretoAna Cláudia Barbin SpinosaBarbara de Souza GutierresGilberto LopesAuro del GiglioPedro Nazareth Aguiar JrIn the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2- advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment. In this review, we summarize all available data, highlight the unanswered questions, and discuss pharmacological differences between each CDK4/6 inhibitor.https://www.drugsincontext.com/a-paradigm-shift-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hr-her2-advanced-breast-cancer-a-review-of-cdk-inhibitorsbreast cancertargeted therapyendocrine therapycyclin-dependent kinase 4cyclin-dependent kinase 6 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mariane Teodoro Fernandes Jacob J Adashek Carmelia Maria Noia Barreto Ana Cláudia Barbin Spinosa Barbara de Souza Gutierres Gilberto Lopes Auro del Giglio Pedro Nazareth Aguiar Jr |
spellingShingle |
Mariane Teodoro Fernandes Jacob J Adashek Carmelia Maria Noia Barreto Ana Cláudia Barbin Spinosa Barbara de Souza Gutierres Gilberto Lopes Auro del Giglio Pedro Nazareth Aguiar Jr A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors Drugs in Context breast cancer targeted therapy endocrine therapy cyclin-dependent kinase 4 cyclin-dependent kinase 6 |
author_facet |
Mariane Teodoro Fernandes Jacob J Adashek Carmelia Maria Noia Barreto Ana Cláudia Barbin Spinosa Barbara de Souza Gutierres Gilberto Lopes Auro del Giglio Pedro Nazareth Aguiar Jr |
author_sort |
Mariane Teodoro Fernandes |
title |
A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors |
title_short |
A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors |
title_full |
A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors |
title_fullStr |
A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors |
title_full_unstemmed |
A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors |
title_sort |
paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (hr+/her2-) advanced breast cancer: a review of cdk inhibitors |
publisher |
BioExcel Publishing Ltd |
series |
Drugs in Context |
issn |
1740-4398 1740-4398 |
publishDate |
2018-11-01 |
description |
In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2- advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment. In this review, we summarize all available data, highlight the unanswered questions, and discuss pharmacological differences between each CDK4/6 inhibitor. |
topic |
breast cancer targeted therapy endocrine therapy cyclin-dependent kinase 4 cyclin-dependent kinase 6 |
url |
https://www.drugsincontext.com/a-paradigm-shift-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hr-her2-advanced-breast-cancer-a-review-of-cdk-inhibitors |
work_keys_str_mv |
AT marianeteodorofernandes aparadigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT jacobjadashek aparadigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT carmeliamarianoiabarreto aparadigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT anaclaudiabarbinspinosa aparadigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT barbaradesouzagutierres aparadigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT gilbertolopes aparadigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT aurodelgiglio aparadigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT pedronazarethaguiarjr aparadigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT marianeteodorofernandes paradigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT jacobjadashek paradigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT carmeliamarianoiabarreto paradigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT anaclaudiabarbinspinosa paradigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT barbaradesouzagutierres paradigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT gilbertolopes paradigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT aurodelgiglio paradigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors AT pedronazarethaguiarjr paradigmshiftforthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativehrher2advancedbreastcancerareviewofcdkinhibitors |
_version_ |
1725324055068803072 |